Ultime notizie per Actinium Pharma (AMEX:ATNM) Azioni

Actinium Pharma

Actinium Pharmaceuticals

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGRI

ATNM

ATPC

BJDX

CHGG

CNSP

HPAI

LCID

LUMN

PLTR

RXST

SERV

SMFG

SPWR

TENK

TPET

UPXI

Pre-market: Palantir guida i rialzi con un +9,6%, mentre SunPower e Chegg mostrano cali significativi. Scopri i dettagli.

Chi sale e chi scende: i maggiori movimenti nel pre-market di oggi

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharmaceuticals Inc

Biotech

General

Actinium Pharmaceuticals Publishes Phase 3 SIERRA Trial Results Of Iomab-B In Journal Of Clinical Oncology, Highlights Success In Achieving Complete Remission And Event-Free Survival

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) with a Buy and lowers the price target from $50 to $4.

Price Target

Analyst Ratings

5HC Wainwright & Co. Maintains Buy on Actinium Pharma, Lowers Price Target to $4

WIIM

Actinium Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS results.

Actinium Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.43) by 11.63 percent.

Earnings

Actinium Pharmaceuticals Q2 2024 GAAP EPS $(0.38) Beats $(0.43) Estimate

Maxim Group analyst Jason McCarthy maintains Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) with a Buy and lowers the price target from $30 to $5.

Maxim Group Maintains Buy on Actinium Pharma, Lowers Price Target to $5

Shares of Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/08/40172453/palantir-q2-earnings-revenue-beat-eps-beat-customer-count-up-41-driven-by-strength-in-us-commercial">second-quarter results</a>.
Palantir reported second-quarter revenue of $678.13 million, beating the consensus estimate of $652.1 million, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Palantir reported second-quarter adjusted earnings of 9 cents per share, beating analyst estimates of 8 cents per share.
Palantir Technologies shares surged 9.6% to $26.40 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>) rose 79.1% to $2.56 in today's pre-market trading after dipping over 12% on Monday.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) gained 44.8% to $3.75 in pre-market trading after the company announced it secured $5 billion in new business from companies seeking to quickly secure their fiber capacity.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) gained 28.7% to $0.25 in pre-market trading after tumbling over 22% on Monday.</li>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRI#NASDAQ">AGRI</a>) jumped 27% to $0.0725 in pre-market trading after falling more than 5% on Monday.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares gained 26.6% to $0.1570 in pre-market trading after dipping 18% on Monday.</li>
<li>Rxsight Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) shares gained 22.7% to $50.00 in pre-market trading after the company posted upbeat second-quarter sales and raised its FY24 revenue forecast.</li>
<li>Serve Robotics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) shares rose 15.3% to $15.70 in pre-market trading after falling around 7% on Monday.</li>
<li>Lucid Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) shares gained 13% to $3.39 in pre-market trading after the company reported better-than-expected second-quarter sales results and announced a $1.5 billion public investment fund commitment.</li>
<li>DDC Enterprise Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDC#NYSE">DDC</a>) shares rose 10.8% to $0.5159 in pre-market trading following around 13% surge on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) shares dipped 24.6% to $0.61 in pre-market trading. SunPower announced a $45 million asset sale to complete Solaria and filed Chapter 11 to maximize asset value.</li>
<li>Chegg Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) shares declined 18.7% to $2.38 in pre-market trading following second-quarter results.</li>
<li>Actinium Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NASDAQ">ATNM</a>) declined 15.3% to $2.10 in pre-market trading after dipping 60% on Monday. On Monday, the FDA determined that Actinium Pharmaceuticals&#8217; Phase 3 SIERRA trial is not adequate to support a Biologics License Application (BLA) filing for Iomab-B despite its statistically significant primary endpoint.</li>
<li>ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) shares declined 15.2% to $8.31 in pre-market trading after the company reported worse-than-expected financial results for the second quarter and announced a management transition. The company announced that CFO Cameron Hyzer will step down from his role. Hyzer will remain in an advisory capacity until Oct. 7 to help facilitate a smooth transition. Graham O&#8217;Brien has been named interim CFO, effective Sept. 6.</li>
<li>Helport AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPAI#NASDAQ">HPAI</a>) shares fell 15.2% to $7.15 in pre-market trading after declining 24% on Monday.</li>
<li>TenX Keane Acquisition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENK#NASDAQ">TENK</a>) fell 14.1% to $31.00 pre-market trading. TenX Keane shares jumped 193% on Monday after shareholders approved the combination with Citius Pharma&#8217;s oncology subsidiary.</li>
<li>Upexi Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) fell 12.4% to $0.25 in today's pre-market trading.</li>
<li>Bluejay Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares fell 11.8% to $0.4010 in pre-market trading after declining 18% on Monday.</li>
<li>Trio Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NYSE">TPET</a>) shares fell 11.2% to $0.2594 in pre-market trading after gaining more than 19% on Monday.</li>
<li>Sumitomo Mitsui Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMFG#NYSE">SMFG</a>) fell 10.5% to $10.80 in pre-market trading after declining around 4% on Monday.</li>
</ul>
Now Read This: 
<ul>
<li>D<a href="https://www.benzinga.com/news/earnings/24/08/40178833/dow-records-worst-day-in-around-2-years-mag-7-stocks-lose-650b-in-market-capitalization-greed-index">ow Records Worst Day In Around 2 Years, Mag 7 Stocks Lose $650B In Market Capitalization: Greed Index Moves To &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>

Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket

U.S. stocks traded lower toward the end of trading, with the S&amp;P 500 dipping more than 100 points on Monday.
The Dow traded down 2.3% to 38,852.44 while the NASDAQ fell 3.19% to 16,241.09. The S&amp;P 500 also fell, dropping, 2.64% to 5,205.37.
Leading and Lagging Sectors Industrials shares fell by just 1.4% on Monday.
In trading on Monday, information technology shares dipped by 3.5%.
Top Headline The ISM services PMI climbed to 51.4 in July from 48.8 in April and also topping market expectations of 51.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Kellanova &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) shares shot up 15% to $72.49 following a report suggesting Mars is considering an acquisition of the company.</li>
<li>Shares of Sotera Health Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHC#NASDAQ">SHC</a>) got a boost, surging 8% to $14.21&nbsp;after the company reported better-than-expected quarterly financial results.</li>
<li>TenX Keane Acquisition &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENK#NASDAQ">TENK</a>) shares were also up, gaining 129% to $28.20 after shareholders approved the combination with Citius Pharma&#8217;s oncology subsidiary.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Actinium Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NASDAQ">ATNM</a>) shares dropped 64% to $2.2001. On Monday, the FDA determined that Actinium Pharmaceuticals' Phase 3 SIERRA trial is not adequate to support a Biologics License Application (BLA) filing for Iomab-B despite its statistically significant primary endpoint.</li>
<li>Shares of VBI Vaccines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIV#NASDAQ">VBIV</a>) were down 29% to $0.0664. VBI Vaccines was notified that its common shares will be delisted from Nasdaq effective as of opening of business on Aug. 8.</li>
<li>Concord Medical Services Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) was down, falling 18% to $7.22.</li>
</ul>
Commodities In commodity news, oil traded down 0.4% to $73.21 while gold traded down 0.8% at $2,449.30.
Silver traded down 3.8% to $27.315 on Monday, while copper fell 2.5% to $4.0000.
Euro zone
European shares closedlower today. The eurozone's STOXX 600 fell 2.17%, Germany's DAX fell 1.82% and France's CAC 40 fell 1.42%. Spain's IBEX 35 Index fell 2.34%, while London's FTSE 100 fell 2.04%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 dipping 12.4%, Hong Kong's Hang Seng Index falling 1.46%, China's Shanghai Composite Index falling 1.54% and S&amp;P BSE Sensex declining 2.74%.
Economics
<ul>
<li>The ISM services PMI climbed to 51.4 in July from 48.8 in April and also topping market expectations of 51.</li>
<li>The S&amp;P Global composite PMI was revised lower to 54.3 in July versus the preliminary reading of 55.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40142776/wall-streets-most-accurate-analysts-views-on-3-materials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Materials Stocks Delivering High-Dividend Yields</a></li>
</ul>

Eurozone

Commodities

Intraday Update

VBIV

S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge

U.S. stocks traded lower midway through trading, with the Dow Jones falling more than 950 points on Monday.
The Dow traded down 2.44% to 38,767.64 while the NASDAQ fell 3.12% to 16,252.09. The S&amp;P 500 also fell, dropping, 2.71% to 5,201.74.
Leading and Lagging Sectors Real estate shares fell by just 0.5% on Monday.
In trading on Monday, information technology shares dipped by 3.2%.
Top Headline The ISM services PMI climbed to 51.4 in July from 48.8 in April and also topping market expectations of 51.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Kellanova &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) shares shot up 13% to $71.36 following a report suggesting Mars is considering an acquisition of the company.</li>
<li>Shares of Sotera Health Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHC#NASDAQ">SHC</a>) got a boost, surging 10% to $14.57&nbsp;after the company reported better-than-expected quarterly financial results.</li>
<li>Sonic Automotive, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>) shares were also up, gaining 9% to $60.76 following better-than-expected earnings.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Actinium Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NASDAQ">ATNM</a>) shares dropped 74% to $1.5850. On Monday, the FDA determined that Actinium Pharmaceuticals' Phase 3 SIERRA trial is not adequate to support a Biologics License Application (BLA) filing for Iomab-B despite its statistically significant primary endpoint.</li>
<li>Shares of VBI Vaccines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIV#NASDAQ">VBIV</a>) were down 34% to $0.0620. VBI Vaccines was notified that its common shares will be delisted from Nasdaq effective as of opening of business on Aug. 8.</li>
<li>Concord Medical Services Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) was down, falling 26% to $6.56.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $73.36 while gold traded down 0.8% at $2,449.30.
Silver traded down 3.2% to $27.49 on Monday, while copper fell 1.7% to $4.0350.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 2.30%, Germany's DAX fell 2.01% and France's CAC 40 fell 1.63%. Spain's IBEX 35 Index fell 2.35%, while London's FTSE 100 fell 2.11%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 dipping 12.4%, Hong Kong's Hang Seng Index falling 1.46%, China's Shanghai Composite Index falling 1.54% and S&amp;P BSE Sensex declining 2.74%.
Economics
<ul>
<li>The ISM services PMI climbed to 51.4 in July from 48.8 in April and also topping market expectations of 51.</li>
<li>The S&amp;P Global composite PMI was revised lower to 54.3 in July versus the preliminary reading of 55.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/24/08/40142776/wall-streets-most-accurate-analysts-views-on-3-materials-stocks-delivering-high-dividend-yields"> Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Materials Stocks Delivering High-Dividend Yields</a>

Dow Tumbles 950 Points; ISM Services PMI Surges In July

On Monday, the FDA determined that Actinium Pharmaceuticals, Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>)&nbsp;Phase 3 SIERRA trial is not adequate to support a Biologics License Application&nbsp;(BLA) filing for Iomab-B despite its statistically <a target="_blank" href="https://www.benzinga.com/news/23/02/30986777/whats-going-on-with-actinium-pharmaceuticals-stock" rel="noreferrer noopener">significant primary endpoint</a>.
The company announced a regulatory update on its planned BLA Biologics License Application seeking approval for Iomab-B in patients with active relapsed or refractory <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/n40156635/actinium-provides-regulatory-update-on-planned-bla-filing-and-future-plans-for-iomab-b-in-the-u-s" rel="noreferrer noopener">acute myeloid leukemia (r/r AML)</a>.
The FDA has advised Actinium to conduct a head-to-head study to evaluate allogeneic bone marrow transplant (BMT) using Iomab-B plus a reduced intensity conditioning regimen of fludarabine and total body irradiation (Flu/TBI) versus allogeneic BMT using reduced intensity conditioning comprised of cyclophosphamide plus Flu/TBI, a difference from the SIERRA trial, which had allowed physician&#8217;s choice of salvage therapies and heterogenous conditioning regimens in the control arm.
Additionally, the proposed new study will not allow patients to crossover from the control arm, which was allowed in the SIERRA trial and confounded the overall survival analysis in the intent-to-treat (ITT) patient population, as nearly 60% of patients <a target="_blank" href="https://www.benzinga.com/general/biotech/22/10/29483275/actinium-shares-are-trading-higher-after-positive-data-from-acute-myeloid-leukemia-trial" rel="noreferrer noopener">crossed over from the control arm</a>.
In&nbsp;February 2023, Actinium announced that the SIERRA trial met the primary endpoint with statistical significance as 22% of patients (13/76) on the Iomab-B arm achieved dCR compared to 0% of patients (0/77).
The SIERRA trial was conducted in accordance with guidance from the FDA&#8217;s End of Phase 2 meeting, which stated that positive results for dCR as the primary endpoint would be acceptable to support an Iomab-B BLA filing.
SIERRA did not meet the secondary endpoint of overall survival on an intent-to-treat basis analysis due to the high crossover rate, with nearly 60% of control arm patients receiving Iomab-B followed by a BMT.
Upon concluding its interactions with the FDA, Actinium will seek a strategic partner for Iomab-B in the U.S.
Price Action: ATNM stock is down 74% at $1.59 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40157789/biontechs-q2-loss-widens-amid-low-demand-for-its-pfizer-partnered-covid-19-vaccine-increases-r-d-" target="_blank" rel="noreferrer noopener">BioNTech&#8217;s Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&amp;D Spending On New Cancer Products</a>.</li>
</ul>
Photo: Shutterstock

Health Care

Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment

U.S. stocks traded lower this morning, with the Dow Jones falling more than 2% on Monday.
The Dow traded down 2.18% to 38,872.06 while the NASDAQ fell 3.14% to 16,248.99. The S&amp;P 500 also fell, dropping, 2.54% to 5,211.01.
Leading and Lagging Sectors Real estate shares fell by just 0.9% on Monday.
In trading on Monday, information technology shares dipped by 3.4%.
Top Headline Tyson Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) reported better-than-expected third-quarter earnings on Monday.
Quarterly adjusted earnings per share of 87 cents (+480%) beat the street view of 65 cents. Sales of $13.353 billion (+1.6%) beat the analyst consensus of $13.236 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) shares shot up 55% to $3.99 after gaining over 5% on Friday.</li>
<li>Shares of Beasley Broadcast Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>) got a boost, surging 25% to $0.6259&nbsp;.</li>
<li>Kernel Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNL#NASDAQ">KRNL</a>) shares were also up, gaining 25% to $13.99.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Actinium Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NASDAQ">ATNM</a>) shares dropped 72% to $1.7006 after the FDA determined that its Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B.</li>
<li>Shares of VBI Vaccines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIV#NASDAQ">VBIV</a>) were down 34% to $0.0615. VBI Vaccines was notified that its common shares will be delisted from Nasdaq effective as of opening of business on Aug. 8.</li>
<li>Urgent.ly Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULY#NASDAQ">ULY</a>) was down, falling 32% to $0.9699. Urgently will host a conference call on Monday, Aug. 12 to discuss its financial results for the second quarter.</li>
</ul>
Commodities In commodity news, oil traded down 0.5% to $73.05 while gold traded down 1.5% at $2,433.40.
Silver traded down 4% to $27.265 on Monday, while copper fell 2.1% to $4.0160.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 2.5%, Germany's DAX fell 2.5% and France's CAC 40 fell 2.1%. Spain's IBEX 35 Index fell 2.5%, while London's FTSE 100 fell 2.6%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 dipping 12.4%, Hong Kong's Hang Seng Index falling 1.46%, China's Shanghai Composite Index falling 1.54% and S&amp;P BSE Sensex declining 2.74%.
Economics
<ul>
<li>The ISM services PMI climbed to 51.4 in July from 48.8 in April and also topping market expectations of 51.</li>
<li>The S&amp;P Global composite PMI was revised lower to 54.3 in July versus the preliminary reading of 55.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/24/08/40142776/wall-streets-most-accurate-analysts-views-on-3-materials-stocks-delivering-high-dividend-yields"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40142776/wall-streets-most-accurate-analysts-views-on-3-materials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Materials Stocks Delivering High-Dividend Yields</a><a href="https://www.benzinga.com/markets/24/08/40142776/wall-streets-most-accurate-analysts-views-on-3-materials-stocks-delivering-high-dividend-yields"> </a></li>
</ul>

BBGI

KRNL

MGOL

Nasdaq Tumbles 3%; Tyson Foods Earnings Top Views

<ul>
<li>Additional head-to-head randomized clinical trial demonstrating overall survival benefit with Iomab-B is required by FDA to support a BLA filing.</li>
<li>Actinium to request a meeting with the FDA to further discuss specifics of additional trial.</li>
<li>Actinium will seek strategic partner for Iomab-B in the U.S. following completion of FDA interactions and focus development efforts on Actimab-A, Iomab-ACT and preclinical programs</li>
</ul>

FDA Determines That Actinium Pharmaceuticals' Phase 3 Sierra Trial Is Not Adequate To Support A BLA Filing For Iomab-B For Relapsed Or Refractory Acute Myeloid Leukemia, Despite Its Statistically Significant Primary Endpoint

Actinium shares are trading lower after the FDA determined that its Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B.

Actinium Pharmaceuticals Received U.S. Patent Extending Into 2040 And Covers Methods Using Iomab-ACT For Conditioning Patients Prior To The Administration Of Gene-edited Hematopoietic Stem Cell Therapy To Treat Non-malignant Disorders

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) with a Buy and maintains $50 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price Target

Collaboration With Columbia University Aims To Broaden Access To Cellular Therapies And Inform Gene Therapy Conditioning Study

Actinium Pharmaceuticals Announces FDA Clearance For IND Application To Study Iomab-ACT As Targeted Conditioning Prior To Bone Marrow Transplant In Sickle Cell Disease Patients

- Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors
- Combination with leading menin inhibitor demonstrates acute myeloid leukemia cell death and significant tumor elimination not achieved with&nbsp;monotherapy
- Menin combination expands backbone potential of Actimab-A in acute myeloid leukemia that already includes chemotherapy, venetoclax and FLT3 inhibitors
&nbsp;

Events

Actinium Presents Data Demonstrating Actimab-A In Combination With Leading Menin Inhibitors With Its ARC Actimab-A In Acute Myeloid Leukemia At 2024 EHA Congress

-&nbsp; Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial
-&nbsp; Long-term efficacy results in patients with active relapsed or refractory acute myeloid leukemia also observed in the SIERRA trial
NEW YORK, June 14, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented at the 2024 European Hematology Association (EHA) Hybrid Congress being held June 13 – 16, 2024, in Madrid, Spain. The two presentations at EHA highlighted outcomes in patients with active relapsed or refractory acute myeloid leukemia (r/r AML) enrolled in the SIERRA trial who had a TP53 mutation and long-term efficacy results in this older patient population.

Actinium Presents Oral Presentation Featuring Improved Outcomes In TP53 Patients Receiving Iomab-B In The Phase 3 SIERRA Trial At EHA 2024 Annual Congress

Actinium Highlights Data From Completed Phase 1b Combination Trial Of Actimab-A + CLAG-M In r/r AML At 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

<ul>
<li>Iomab-B led bone marrow transplant improved survival in patients with high-risk relapsed or refractory acute myeloid leukemia including those with a TP53 mutation</li>
<li>Iomab-B safely delivered radiation to the target bone marrow at greater amounts than achievable with total body irradiation while sparing healthy non-target organs and enabled 100% access to bone marrow transplant</li>
<li>Novel linker technology supports Actinium's Antibody Radiation Conjugate pipeline expansion in solid tumor indications</li>
</ul>
NEW YORK, June 10, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today highlighted data from multiple abstracts that were presented at the 2024 Society of Nuclear Medicine &amp; Molecular Imaging (SNMMI) Annual Meeting being held June 8 – 11, 2024, in Toronto, Canada. The presentations featured results from the Phase 3 SIERRA trial of Iomab-B, a CD45 targeting ARC with the Iodine-131 payload, intended for conditioning to prepare patients with active relapsed or refractory acute myeloid leukemia (r/r AML) for a potentially curative bone marrow transplant (BMT). The Phase 3 SIERRA trial enrolled 153 r/r AML patients. Iomab-B achieved the primary endpoint of durable Complete Remission (dCR) with high statistical significance (p&lt;0.0001). Additionally, Actinium's novel linker technology was highlighted in a presentation demonstrating high tumor uptake and in vivo stability in preclinical models with significantly lower kidney and liver uptake compared to standard DOTA linkers.

Actinium Highlights Mutation Data From The Phase 3 SIERRA Trial Of Iomab-B And Novel Linker Technology To Support Solid Tumor Antibody Radiation Conjugate Development At The 2024 SNMMI Annual Meeting

Actinium wins FDA nod to conduct clinical trial for radiotherapy

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), retaining the price targe...

Optimistic Buy Rating for Actinium Pharmaceuticals Amid Iomab-ACT Advancements and Expanding Market Opportunities

Actinium Pharmaceuticals (ATNM) has shared an update. Actinium Pharmaceuticals, Inc. has announced an upcoming regulatory filing for Iomab-B, aimed...

Actinium Pharmaceuticals Advances Iomab-B Regulatory Filing

Actinium stock tumbles 75% on FDA update for lomab-B

Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Actinium Pharmaceuticals (ATNM – Research Report). The associated price ta...

Buy Rating Affirmed for Actinium Pharmaceuticals Amid Strategic Pipeline Focus and European Market Progress

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Actinium Pharmaceuticals (NYSEMKT:<a href="https://investorplace.com/stock-quotes/atnm-stock-quote/">ATNM</a>) just reported results for the second quarter of 2024.<ul><li>Actinium Pharmaceuticals reported earnings per share of -38 cents. This was above the analyst estimate for EPS of -40 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/atnm-stock-earnings-actinium-pharmaceuticals-for-q2-of-2024/">ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q2 2024

Maxim Group analyst Jason McCarthy has maintained their bullish stance on ATNM stock, giving a Buy rating yesterday. Jason McCarthy has given his B...

Buy Rating Affirmed for Actinium Pharmaceuticals Amidst Promising Pipeline and Strong Cash Position

Novartis expands U.S. radiopharma production amid rising competition

Perspective gets FDA fast track status for radiopharmaceutical VMT101

Perspective gets FDA fast track status for radiopharmaceutical VMT01

BAYRY

BLUE

CASI

CATX

CLRB

CRSP

GEHC

LNTH

NVSEF

TLPPF

VRTX

Screenshot 2024-02-29 at 7.16.11 PM

COEP

Here&#39;s How Coeptis Therapeutics Is Innovating Cell Therapy Approaches

Legal

Press Releases

Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

The Future of Medicine: Key Biotech Stocks to Watch

Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM

Transforming Cancer Therapy Stocks to Watch In The Oncology Sector

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology

Comments

Actinium Pharma

Notizie

Ultime notizie per Actinium Pharma (AMEX:ATNM) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO